NRx CEO presented plans for HOPE Therapeutics rollout in September 2025 and establishment of flagship location in Palm Beach, FL...
Collaboration to advance data management, AI and generative AI capabilities Integration of shop floor data made available via Siemens Industrial...
VANCOUVER, BC / ACCESS Newswire / September 2, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:XPHYF)(FSE:4XT) is...
DUBLIN--(BUSINESS WIRE)--The "United States Data Center Construction Market Report and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering. The...
The digital pathology market is anticipated to increase due to the global increase in chronic conditions like cancer, cardiovascular disorders,...
DELRAY BEACH, Fla., Sept. 1, 2025 /PRNewswire/ -- The global Contract Research Organization Services Market, valued at US$79.10 billion in...
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS...
Black Book Flash Survey of VCs, PEs, Bankers, Analysts and Influencers Reveals Q4's Hottest Healthcare Investment NEW YORK CITY, NY...
KFSHRC to Participate as Strategic Partner in C3 Davos of Healthcare ™ New York Summit A glimpse from KFSHRC’s presence...
Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded...
ZUG, Switzerland, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis...
DALLAS, Aug. 31, 2025 /PRNewswire/ -- At Taiwan Expo USA 2025 in Dallas, the Smart Healthcare Pavilion, organized by the...
Largest Health Systems AI 2025 comprehensive survey to date highlights adoption momentum and governance gap in U.S. hospitals CHICAGO, IL...
After the EPA dismissed employees who publicly criticized its leadership, attention is turning to the Drug Enforcement Administration's Diversion Control...
Why Weight Loss Feels Impossible After 35 NEW YORK CITY, NY / ACCESS Newswire / August 31, 2025 / For...
Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart attack, stroke...
KFSHRC Strengthens Its Position as a Fast-Growing Destination for International Patients KFSHRC recorded a 47% surge in international patients in...
V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C)...
Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3In the...
MIAMI, FL / ACCESS Newswire / August 30, 2025 / In today's fast-paced world, maintaining mental sharpness, focus, and memory...